Multiple Myeloma Market Size to Touch USD 31 billion, with 6.0% CAGR by 2026

The global multiple myeloma market size is projected to reach USD 31 billion by the end of 2026. The high prevalence of the disease will emerge in favor of the companies operating in the market. According to a report published by Fortune Business Insights, titled “Multiple Myeloma Market Size, Share & Industry Analysis, By Drug Class (Immunomodulators, Proteasome Inhibitor, Anti-CD38 Monoclonal Antibody, Alkylating Agents, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies), and Regional Forecast, 2019-2026,” the market was worth USD 19.48 billion in 2018 and will exhibit a CAGR of 6.0% during the forecast period, 2019-2026.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-myeloma-market-102693

Highlights of the Report:

• In-depth analysis of various insights, namely, Multiple Myeloma Market trends, growth drivers, opportunities, and other related challenges.
• Comprehensive details of key market players, their core competencies, and Multiple Myeloma Market share.
• The potency of suppliers and buyers to make better business decisions.
• Lists out the market size in terms of volume.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/multiple-myeloma-market-102693
Key Players Operating in The Multiple Myeloma Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Takeda Pharmaceutical Company Limited
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Bristol Myers Squibb Company
• Amgen Inc.
• ONO PHARMACEUTICAL CO., LTD.
• Janssen Pharmaceuticals, Inc.
• Genentech, Inc. (F. Hoffmann-La Roche Ltd)
• CELGENE CORPORATION (Bristol Myers Squibb Company)
• AbbVie Inc.
• Sanofi
• Karyopharm
• Others

Detailed Table of Content:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Multiple Myeloma - by Key Countries - 2018
4.2. Pipeline Analysis
4.3. Key Industry Developments
4.4. Regulatory Scenario, by Key Regions
4.5. Analysis Of Economic Burden of Multiple Myeloma Treatment
4.6. New Product Launches
4.7. Overview of Emerging Treatments for Multiple Myeloma
5. Global Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1. Immunomodulators
5.2.2. Proteasome Inhibitor
5.2.3. Anti-CD38 Monoclonal Antibody
5.2.4. Alkylating Agents
5.2.5. Others
5.3. Market Analysis, Insights and Forecast – By Distribution Channel
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies & Drug Stores
5.3.3. Online Pharmacies
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Latin America
5.4.5. Middle East & Africa
6. North America Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Class
6.2.1. Immunomodulators
6.2.2. Proteasome Inhibitor
6.2.3. Anti-CD38 Monoclonal Antibody
6.2.4. Alkylating Agents
6.2.5. Others
6.3. Market Analysis – By Distribution Channel
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies & Drug Stores
6.3.3. Online Pharmacies
6.4. Market Analysis – By Country
6.4.1. U.S.
6.4.2. Canada
7. Europe Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis – By Drug Class
7.2.1. Immunomodulators
7.2.2. Proteasome Inhibitor
7.2.3. Anti-CD38 Monoclonal Antibody
7.2.4. Alkylating Agents
7.2.5. Others
7.3. Market Analysis – By Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies & Drug Stores
7.3.3. Online Pharmacies
7.4. Market Analysis – By Country/ sub-region
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Spain
7.4.5. Italy
7.4.6. Scandinavia
7.4.7. Rest of Europe
8. Asia pacific Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis – By Drug Class
8.2.1. Immunomodulators
8.2.2. Proteasome Inhibitor
8.2.3. Anti-CD38 Monoclonal Antibody
8.2.4. Alkylating Agents
8.2.5. Others
8.3. Market Analysis – By Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies & Drug Stores
8.3.3. Online Pharmacies
8.4. Market Analysis – By Country/ sub-region
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Southeast Asia
8.4.6. Rest of Asia Pacific
9. Latin America Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
9.1. Key Findings / Summary
9.2. Market Analysis – By Drug Class
9.2.1. Immunomodulators
9.2.2. Proteasome Inhibitor
9.2.3. Anti-CD38 Monoclonal Antibody
9.2.4. Alkylating Agents
9.2.5. Others
9.3. Market Analysis – By Distribution Channel
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies & Drug Stores
9.3.3. Online Pharmacies
9.4. Market Analysis – By Country/ sub-region
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America

Continued...

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.